Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eliquis, Bydureon Launches Still A Wait-And-See Story For Bristol

This article was originally published in The Pink Sheet Daily

Executive Summary

Investors are focused on the launch of both drugs, which are expected to contribute meaningfully to Bristol’s return to growth, as well as on nivolumab, a promising anti-PD-1 in development for cancer. Few conclusions can be drawn on any of those fronts from the company’s first quarter financial update.

You may also be interested in...



Bristol-Myers Squibb And Bayer Keep The Focus On China: Emerging Markets Earnings Roundup (Part 2)

During Q1, BMS welcomed its new R&D president and also saw new products launched in China, while Bayer’s mature products reported strong growth in China.

Incoming Bristol R&D Chief Cuss Initially Plans To Follow Sigal’s Course Of Action

Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.

Eliquis Label Looks Great, But May Leave Door Open For Pradaxa To Compete On Efficacy

Bristol/Pfizer’s Eliquis secures an attractive FDA label for atrial fibrillation on three key fronts: superior stroke prevention, reduced major bleeding and reduced all-cause mortality. With its superiority in preventing hemorrhagic strokes, Eliquis has the clear lead in terms of safety. But Boehringer’s competing Pradaxa remains the only new oral anticoagulant with proven superiority for preventing purely ischemic strokes, which is the main goal of atrial fibrillation treatment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel